SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
SEC Accession No. 0001104659-17-060395
Filing Date
2017-10-03
Accepted
2017-10-03 08:38:35
Documents
3

Document Format Files

Seq Description Document Type Size
1 SC 13D/A a17-22768_1sc13da.htm SC 13D/A 80728
2 EX-7.08 a17-22768_1ex7d08.htm EX-7.08 750867
3 GRAPHIC g227681kg09i001.jpg GRAPHIC 1642
  Complete submission text file 0001104659-17-060395.txt   835667
Mailing Address 100-8900 GLENLYON PARKWAY BURNABY A1 V5J 5J8
Business Address 100-8900 GLENLYON PARKWAY BURNABY A1 V5J 5J8 604-419-3200
Arbutus Biopharma Corp (Subject) CIK: 0001447028 (see all company filings)

IRS No.: 980597776 | Fiscal Year End: 1231
Type: SC 13D/A | Act: 34 | File No.: 005-85963 | Film No.: 171116152
SIC: 2834 Pharmaceutical Preparations

Mailing Address CLARENDON HOUSE 2 CHURCH STREET HAMILTON D0 HM11
Business Address CLARENDON HOUSE, 2 CHURCH STREET HAMILTON HM11 D0 HM11 441-295-5950
Roivant Sciences Ltd. (Filed by) CIK: 0001635088 (see all company filings)

IRS No.: 981173944 | State of Incorp.: D0 | Fiscal Year End: 0331
Type: SC 13D/A